Pfizer: fast track for NASH liver disease
(CercleFinance.com) - Pfizer announced on Thursday that the US Food and Drug Administration (FDA) has granted "fast track" status to the Ervogastat/Clesacostat combination for the treatment of NASH, a liver disease.
The US biopharmaceutical company said that this measure enables the Food and Drug Administration to accelerate the review process of a treatment for a serious disease or previously unmet medical need.
The Ervogastat/Clesacostat combination is currently in Phase II trials, a study that is not expected to be completed until 2024.
Phase 2a clinical trials have previously demonstrated that the Ervogastat/Clesacostat combination reduces liver fat, with a well accepted safety and tolerability profile.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The US biopharmaceutical company said that this measure enables the Food and Drug Administration to accelerate the review process of a treatment for a serious disease or previously unmet medical need.
The Ervogastat/Clesacostat combination is currently in Phase II trials, a study that is not expected to be completed until 2024.
Phase 2a clinical trials have previously demonstrated that the Ervogastat/Clesacostat combination reduces liver fat, with a well accepted safety and tolerability profile.
Copyright (c) 2022 CercleFinance.com. All rights reserved.